Emcure completes acquisition to make Gennova a wholly-owned subsidiary

Listed Co AcquisitionStrategic Transactions View source PDF

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.1%1-day move

₹1880.40

prior close

₹1886.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.7+0.0-0.2-0.5+0.1+1.9————————

Up moveDown movePending

AI summary

Emcure has completed acquiring 663,865 equity shares (12.05%) of Gennova Biopharmaceuticals for Rs. 2,318.7 Million in cash. Gennova is now a wholly-owned subsidiary (up from 87.95%). Gennova's FY26 turnover was Rs. 4,917.42 Million and PAT Rs. 54.25 Million. Transaction is a related party deal done at arm's length.

Likely market impact

Gennova is now fully consolidated within Emcure, boosting biotech business and earnings visibility. Minor cash outflow of about Rs. 232 Crore.